Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:KMDA

Kamada Q3 2026 Earnings Date & Estimates

Kamada logo
$7.78 +0.19 (+2.43%)
As of 10:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Kamada is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Kamada in Q3 2026

Kamada is expected to post earnings of $0.13 per share on revenue of $52.51 million. In the same quarter a year earlier Kamada reported $0.09 per share on revenue of $47.01 million. Kamada last reported on August 12, 2026, posting $0.16 per share and beating the $0.1125 consensus estimate. Kamada has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.13
Expected Revenue
$52.51 million
Prior-Year EPS
$0.09
Prior-Year Revenue
$47.01 million
Expected EPS Growth
+44.4%
Expected Revenue Growth
+11.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.16 (Beat by +$0.0475)
Last Quarter Revenue
$54.92 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Kamada Q3 2026 Earnings FAQ

Kamada (NASDAQ:KMDA) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Kamada's Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Kamada to post earnings of $0.13 per share for Q3 2026.

The consensus revenue estimate for Kamada is $52.51 million for Q3 2026.

Kamada Earnings Headlines

Kamada (NASDAQ:KMDA) Stock Price Breaks Below 200 Day Moving Average - Here's Why
October 14 at 3:42 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31118202
Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel
October 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/kamada-launches-ustekinumab-enoxaparin-biosimilars-114953619.html
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
October 15 at 1:00 AM  |  Profits Run (Ad)
Kamada (NASDAQ: KMDA) expands biosimilars portfolio with 2030 revenue guide
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31092753
Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375311/0/en/kamada-announces-expansion-of-biosimilars-portfolio-with-the-launch-of-two-additional-products-in-israel.html
Kamada Corrects SEC Filing Error and Commits to Clearer Inventory Accounting Disclosures
October 5, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/kamada-corrects-sec-filing-error-and-commits-to-clearer-inventory-accounting-disclosures?utm_source=marketbeat.com&utm_medium=referral
See More Kamada Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kamada? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kamada and other key companies, straight to your email.

About Kamada

Kamada (NASDAQ:KMDA) is an Israeli biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapies. The company’s products are designed to treat rare diseases, immune deficiencies and other serious medical conditions, with an emphasis on specialty biologic medicines and immunoglobulin-based treatments.

Kamada’s portfolio includes Glassia, an alpha-1 antitrypsin augmentation therapy for patients with alpha-1 antitrypsin deficiency; KEDRAB, a human rabies immune globulin used for post-exposure prophylaxis; WINRHO SDF, an immune globulin product; and CYTOGAM, a cytomegalovirus immune globulin. The company also develops additional plasma-derived and immunoglobulin therapies through internal research and strategic collaborations.

Founded in 1990, Kamada is headquartered in Rehovot, Israel, and serves healthcare markets in the United States, Israel and other international geographies through direct commercial operations and distribution partnerships. Amir London has served as the company’s chief executive officer, overseeing its expansion as a specialty biopharmaceutical business.

View Kamada Profile
Earnings Tools